# US 2002/0058610 A1 · Mammary transforming protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058610 A1
- Document ID: US20020058610A1
- Status: Published application
- Kind: A1
- Application number: 09/263,811
- Filed: 1999-03-08
- Published: 2002-05-16
- Earliest claimed: 1995-11-02
- Assignees: Human Genome Sciences, Inc.
- Inventors: JIAN NI; GUO-LIANG YU; REINER L. GENTZ
- Web page: https://patentgrep.com/patent/US20020058610A1

## CPC

- C07K 14/82: Translation products from oncogenes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/026: where the vector is derived from a baculovirus
- C12Q 2600/136: Screening for pharmacological compounds
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A human mammary transforming protein and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for inhibiting such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.

## Claims

### Claim 1

An isolated polynucleotide comprising a polynucleotide having at least 95% identity to a member selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide comprising amino acid 2 to 74 of SEQ ID NO:2; and
(b) the complement of (a).

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1 wherein said member is (a).

### Claim 3 (depends on 1)

The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids 1 to 74 of SEQ ID NO:2.

### Claim 4 (depends on 1)

The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence identical to amino acids 2 to 74 of SEQ ID NO:2.

### Claim 5 (depends on 1)

The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.

### Claim 6 (depends on 1)

The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino sequence identical to amino acids 1 to 74 of SEQ ID NO:2.

### Claim 7 (depends on 1)

The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.

### Claim 8 (depends on 2)

A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 2 into a vector, wherein said polynucleotide is DNA.

### Claim 9 (depends on 2)

A recombinant vector comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.

### Claim 10 (depends on 2)

A recombinant host cell comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.

### Claim 11 (depends on 10)

A method for producing a polypeptide comprising expressing from the recombinant cell of claim 10 the polypeptide encoded by said polynucleotide.

### Claim 12 (depends on 4)

A process for producing a polypeptide comprising:
expressing from a recombinant cell containing the polynucleotide of claim 4 the polypeptide encoded by said polynucleotide.

### Claim 13 (depends on 6)

A process for producing a polypeptide comprising:
expressing from a recombinant cell containing the polynucleotide of claim 6 the polypeptide encoded by said polynucleotide.

### Claim 14 (depends on 1)

The isolated polynucleotide of claim 1 comprising nucleotides 169 to 387 of SEQ ID NO:1.

### Claim 15 (depends on 1)

The isolated polynucleotide of claim 1 comprising nucleotides 166 to 357 of SEQ ID NO:1.

### Claim 16 (depends on 1)

The isolated polynucleotide of claim 1 comprising the nucleotides of the sequence of SEQ ID NO:1.

### Claim 17

An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:
(a) a polynucleotide encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97300; and
(b) the complement of (a).

### Claim 18 (depends on 17)

The isolated polynucleotide of claim 17, wherein the member is (a).

### Claim 19 (depends on 17)

The isolated polynucleotide of claim 17, wherein said polynucleotide comprises DNA identical to the coding portion of the human cDNA in ATCC Deposit No. 97300 which encodes a mature polypeptide.

### Claim 20 (depends on 4)

An isolated polypeptide comprising:
a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polynucleotide of claim 4.

### Claim 21 (depends on 20)

The isolated polypeptide of claim 20, comprising amino acids 2 to 74 of sequence of SEQ ID NO:2.

### Claim 22 (depends on 20)

The isolated polypeptide of claim 20, comprising amino acids 1 to 74 of sequence of SEQ ID NO:2.

### Claim 23 (depends on 20)

The isolated polypeptide of claim 20 comprising amino acids 1 to 74 of SEQ ID NO:2.

### Claim 24

An isolated polypeptide comprising:
a mature polypeptide encoded by a polynucleotide which is at least 95% identical to the human cDNA contained in ATCC Deposit No. 97300.

### Claim 25 (depends on 24)

The isolated polypeptide of claim 24 comprising the mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97300.

### Claim 26 (depends on 20)

An antibody against the polypeptide of claim 20.

### Claim 27 (depends on 20)

An antagonist against the polypeptide of claim 20.

### Claim 28 (depends on 20)

A method for the treatment of a patient having need of mammary transforming protein comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 20.

### Claim 29 (depends on 25)

The method of claim 25 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

### Claim 30 (depends on 24)

A method for the treatment of a patient having need to inhibit a mammary transforming protein polypeptide comprising:
administering to the patient a therapeutically effective amount of the compound of claim 24.

### Claim 31 (depends on 25)

A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 25 comprising:
determining a mutation in a nucleic acid sequence encoding said polypeptide.

### Claim 32 (depends on 25)

A diagnostic process comprising: analyzing for the presence of the polypeptide of claim 25 in a sample derived from a host.

### Claim 33 (depends on 32)

The diagnostic process of claim 32 wherein said sample is selected from the group consisting of histological sections of mammary sections and blood, and the diagnostic process detects the presence or absence of cancer.

### Claim 34 (depends on 25)

A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 25 comprising:
contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable mammary transforming protein and a compound under conditions to permit binding to the receptor; and
determining whether the compound binds to and inhibits the receptor by detecting the absence of a signal generated from the interaction of the mammary transforming protein with the receptor.
